News
04-02-2017, 10:40 PM
Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.
More... (http://www.news-medical.net/news/20170403/Amgen-UCB-present-romosozumab-Phase-2-results-at-ENDO-2017.aspx)
More... (http://www.news-medical.net/news/20170403/Amgen-UCB-present-romosozumab-Phase-2-results-at-ENDO-2017.aspx)